The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Human papillomavirus and HPV vaccines: a review
Open accessAbstract
Cervical cancer, the most common cancer affecting women in developing countries, is caused by persistent infection with "high-risk" genotypes of human papillomaviruses (HPV). The most common oncogenic HPV genotypes are 16 and 18, causing approximately 70% of all cervical cancers. Types 6 and 11 do not contribute to the incidence of high-grade dysplasias (precancerous lesions) or cervical cancer, but do cause laryngeal papillomas and most genital warts. HPV is highly transmissible, with peak incidence soon after the onset of sexual activity. A quadrivalent (types 6, 11, 16 and 18) HPV vaccine has recently been licensed in several countries following the determination that it has an acceptable benefit/risk profile. In large phase III trials, the vaccine prevented 100% of moderate and severe precancerous cervical lesions associated with types 16 or 18 among women with no previous infection with these types. A bivalent (types 16 and 18) vaccine has also undergone extensive evaluation and been licensed in at least one country. Both vaccines are prepared from non-infectious, DNA-free virus-like particles produced by recombinant technology and combined with an adjuvant. With three doses administered, they induce high levels of serum antibodies in virtually all vaccinated individuals. In women who have no evidence of past or current infection with the HPV genotypes in the vaccine, both vaccines show > 90% protection against persistent HPV infection for up to 5 years after vaccination, which is the longest reported follow-up so far. Vaccinating at an age before females are exposed to HPV would have the greatest impact. Since HPV vaccines do not eliminate the risk of cervical cancer, cervical screening will still be required to minimize cancer incidence. Tiered pricing for HPV vaccines, innovative financing mechanisms and multidisciplinary partnerships will be essential in order for the vaccines to reach populations in greatest need.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smith, J. S., Lindsay, L., Hoots, B., Keys, J., Franceschi, S., Winer, R., & Clifford, G. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22527 · Cited by 1,686
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N., & Franceschi, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600688 · Cited by 1,561
Chapter 2: The burden of HPV-related cancers
Parkin, D. M., & Bray, F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.111 · Cited by 1,385
NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA
RICHART, R. M. (1967) · Clinical Obstetrics and Gynecology · doi:10.1097/00003081-196712000-00002 · Cited by 1,376
Muñoz, N., Bosch, F. X., Castellsagué, X., Díaz, M., de Sanjose, S., Hammouda, D., Shah, K. V., & Meijer, C. J. L. M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20244 · Cited by 1,104
IARC monographs on the evaluation of carcinogenic risks to humans
(1996) · Analytica Chimica Acta · doi:10.1016/s0003-2670(97)89591-8 · Cited by 1,083
Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners
Castellsagué, X., Bosch, F. X., Muñoz, N., Meijer, C. J. L. M., Shah, K. V., de Sanjosé, S., Eluf-Neto, J., Ngelangel, C. A., Chichareon, S., Smith, J. S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011688 · Cited by 804
Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women
Winer, R. L., Hughes, J. P., Feng, Q., O'Reilly, S., Kiviat, N. B., Holmes, K. K., & Koutsky, L. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053284 · Cited by 694
Clifford, G. M., Smith, J. S., Aguado, T., & Franceschi, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601024 · Cited by 684
Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J., Kiviat, N., & Galloway, D. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315498 · Cited by 575
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases
Clifford, G., Franceschi, S., Diaz, M., Muñoz, N., & Villa, L. L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.026 · Cited by 568
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., & Franco, E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh104 · Cited by 539
Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
Lacey, C. J. N., Lowndes, C. M., & Shah, K. V. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.015 · Cited by 535
Clifford, G. M., Rana, R. K., Franceschi, S., Smith, J. S., Gough, G., & Pimenta, J. M. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0812 · Cited by 533
Zhou, J., Sun, X. Y., Stenzel, D. J., & Frazer, I. H. (1991) · Virology · doi:10.1016/0042-6822(91)90772-4 · Cited by 506
Chapter 5: Updating the natural history of HPV and anogenital cancer
Moscicki, A.-B., Schiffman, M., Kjaer, S., & Villa, L. L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.018 · Cited by 478
Villa, L. L., Ault, K. A., Giuliano, A. R., Costa, R. L. R., Petta, C. A., Andrade, R. P., Brown, D. R., Ferenczy, A., Harper, D. M., Koutsky, L. A., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.068 · Cited by 469
Olsson, S.-E., Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Malm, C., Iversen, O.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.049 · Cited by 454
Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide
Franceschi, S., Herrero, R., Clifford, G. M., Snijders, P. J. F., Arslan, A., Anh, P. T. H., Bosch, F. X., Ferreccio, C., Hieu, N. T., Lazcano‐Ponce, E., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22241 · Cited by 415
Castle, P. E., Schiffman, M., Herrero, R., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., Sherman, M. E., Wacholder, S., Tarone, R., & Burk, R. D. (2005) · The Journal of Infectious Diseases · doi:10.1086/428779 · Cited by 403
Muñoz, N., Méndez, F., Posso, H., Molano, M., van den Brule, A. J. C., Ronderos, M., Meijer, C., Muñoz, Á., & Instituto Nacional de Cancerología HPV study group (2004) · The Journal of Infectious Diseases · doi:10.1086/425907 · Cited by 395
Barnabas, R. V., Laukkanen, P., Koskela, P., Kontula, O., Lehtinen, M., & Garnett, G. P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030138 · Cited by 293
Kjær, S. K., Chackerian, B., van den Brule, A. J. C., Svare, E. I., Paull, G., Walbomers, J. M. M., Schiller, J. T., Bock, J. E., Sherman, M. E., Lowy, D. R., et al. (2001) · PubMed · Cited by 269
Findings to Date From the ASCUS-LSIL Triage Study (ALTS)
Schiffman, M., & Solomon, D. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-946-ftdfta · Cited by 249
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., Decarvalho, N. S., et al. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000154423.27940.68 · Cited by 247
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination
Franco, E. L., Cuzick, J., Hildesheim, A., & de Sanjosé, S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.061 · Cited by 236
General Acquisition of Human Papillomavirus Infections of Skin Occurs in Early Infancy
Antonsson, A., Karanfilovska, S., Lindqvist, P. G., & Hansson, B. G. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.6.2509-2514.2003 · Cited by 225
Vaccarella, S., Franceschi, S., Herrero, R., Muñoz, N., Snijders, P. J. F., Clifford, G. M., Smith, J. S., Lazcano-Ponce, E., Sukvirach, S., Shin, H.-R., et al. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0577 · Cited by 202
Insinga, R. P., Dasbach, E. J., & Elbasha, E. H. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523110-00004 · Cited by 195
Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes
Garnett, G. P., Kim, J. J., French, K., & Goldie, S. J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.116 · Cited by 162
Cervical Human Papillomavirus Infection in the Female Population in Barcelona, Spain
de Sanjosé, S., Almirall, R., Lloveras, B., Font, R., Díaz, M., Muñóz, N., Català, I., Meijer, C. J. L. M., Snijders, P. J. F., Herrero, R., et al. (2003) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000080177.82204.e0 · Cited by 157
Chapter 16: HPV vaccines in immunocompromised women and men
Palefsky, J. M., Gillison, M. L., & Strickler, H. D. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.120 · Cited by 110
Franco, E. L., Villa, L. L., Rohan, T. E., Ferenczy, A. S., Petzl‐Erler, M. L., & Matlashewski, G. (1999) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49891999000900001 · Cited by 102
Spectrum of Genital Human Papillomavirus Infection in a Female Adolescent Population
Jamison, J., Kaplan, D. W., Hamman, R. F., Eagar, R., Beach, R. K., & Douglas, J. M. (1995) · Sexually Transmitted Diseases · doi:10.1097/00007435-199507000-00007 · Cited by 76
Preparing for the introduction of HPV vaccines: policy and programme guidance for countries.
Broutet, N. J. N., Huntington, D., Cutts, F. T., & Hall, P. S. (2006) · Cited by 66
Self-citationYoung, T. K., McNicol, P. J., & Beauvais, J. (1997) · Sexually Transmitted Diseases · doi:10.1097/00007435-199705000-00011 · Cited by 55
Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women
Winer, R. L., Hughes, J. P., Feng, Q., O’Reilly, S. F., Kiviat, N. B., Holmes, K. K., & Koutsky, L. A. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000238632.83461.e1 · Cited by 45
Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines
Hildesheim, A., Markowitz, L. E., Hernández‐Ávila, M., & Franceschi, S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.102 · Cited by 16
Cited by
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
The role of infection in miscarriage
Giakoumelou, S., Wheelhouse, N., Cuschieri, K., Entrican, G., Howie, S. E. M., & Horne, A. W. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv041 · Cited by 464
Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases
Berman, T. A., & Schiller, J. T. (2017) · Cancer · doi:10.1002/cncr.30588 · Cited by 395
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
Kamolratanakul, S., & Pitisuttithum, P. (2021) · Vaccines · doi:10.3390/vaccines9121413 · Cited by 263
Infections and cancer: Established associations and new hypotheses
de Martel, C., & Franceschi, S. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.07.021 · Cited by 258
Metadata
- Authors
- Cutts, F.
- Venue
- Bulletin of the World Health Organization
- Publisher
- WHO Press
- Published
- 2007-09-01
- Volume
- 85
- Issue
- 09
- Pages
- 719-726
- ISSN
- 0042-9686 (ISSN-L)
- OpenAlex
- W2157554614
- Cited by
- 370
- References
- 41
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.